<DOC>
	<DOCNO>NCT02246673</DOCNO>
	<brief_summary>This Phase 2a , randomize , open-label , multicenter study assess pharmacodynamic ( PD ) effect safety RDEA3170 administer combination febuxostat compare febuxostat administer alone adult subject gout .</brief_summary>
	<brief_title>RDEA3170 Febuxostat Combination Study Gout Subjects</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Able understand study procedures risk involve willing provide write informed consent first studyrelated activity . Meets one criterion diagnosis gout per American Rheumatism Association Criteria Classification Acute Arthritis Primary Gout . Body weight ≥ 50 kg ( 110 lb ) body mass index ≥ 18 ≤ 45 kg/m2 . Screening serum urate level ≥ 8 mg/dL . Free clinically significant disease medical condition , per Investigator 's judgment . Unable take colchicine gout flare prophylaxis . History suspicion kidney stone . Any gastrointestinal disorder affect motility and/or absorption . Unstable angina , New York Heart Association class III IV heart failure , ischemic heart disease , stroke , deep venous thrombosis within 12 month prior Day 1 ; subject currently receive anticoagulant . Screening laboratory parameter outside normal limit consider clinically significant Investigator . Estimated creatinine clearance &lt; 60 mL/min calculate CockcroftGault formula use ideal body weight Screening period . Taking losartan , fenofibrate , guaifenesin , sodiumglucose link transporter2 inhibitor ; chronic stable dos permit dos stable least 14 day prior study medication dosing . Unable unwilling comply study requirement situation condition , opinion Investigator , may interfere participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>